

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	HER2 (EGFR2; ERBB2; neu)	<p>Mouse studies suggest that adoptive transfer of allogeneic, tumor-targeting T cells could help treat solid tumors. In a mouse model of HER2-expressing metastatic renal cell carcinoma, adoptive transfer of allogeneic T cells modified to express a HER2-targeting antibody increased survival to a similar degree as adoptive transfer of control T cells. In the mice, adoptive transfer of allogeneic HER2-targeting T cells plus injection of fingolimod, which blocks lymphocytic graft-versus-host disease (GvHD) responses, increased survival compared with adoptive transfer of control T cells plus fingolimod. Ongoing work includes testing allogeneic T-bodies in mouse models of spontaneous solid tumors.</p> <p><b>Gilenya fingolimod</b> (FTY720), a sphingosine 1-phosphate receptor agonist from Novartis AG and Mitsubishi Tanabe Pharma Corp., is approved to treat relapsing-remitting multiple sclerosis (RRMS).</p> <p><b>SciBX 4(25); doi:10.1038/scibx.2011.705</b> Published online June 23, 2011</p>	Patented by Yeda Research and Development Co. Ltd.; available for licensing	<p>Marcus, A. <i>et al. Blood</i>; published online June 7, 2011; doi:10.1182/blood-2011-02-334284</p> <p><b>Contact:</b> Zelig Eshhar, Weizmann Institute of Science, Rehovot, Israel e-mail: <a href="mailto:zelig.eshhar@weizmann.ac.il">zelig.eshhar@weizmann.ac.il</a></p>